The CAR consisted of a portion of the EGFRvIII-specific antibody (also called MR1) as a single-chain variable fragment (scFv) that was linked to the DNAX-activating protein 12 (DAP12) domain as an intercellular region for signal transduction, resulting in increased cytotoxicity to cancer cells, the release of pro-inflammatory factors, and extend symptom-free survival in immunocompetent mice [5, 13, 14]. Here, TYROBP is linked to cancer.